Endo’s Lidoderm Mailings Draw FDA Warning Letter For Unsubstantiated Claims
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA asks Endo to disseminate “corrective messages” to doctors who received the violative promotional materials, which the agency says omit risk information and contain unsubstantiated effectiveness claims.
You may also be interested in...
Vantas Brochure Drops Safety Information, Draws Letter From FDA
Endo has received four enforcement letters from FDA since 1999 that cite a failure to include complete and accurate risk information for its products.
Endo’s Lidoderm Marketing Practices Under HHS OIG Investigation
Subpoena asks for documents relating to off-label promotion of pain patch.
Endo’s Lidoderm Marketing Practices Under HHS OIG Investigation
Subpoena asks for documents relating to off-label promotion of pain patch.